Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Worsening of disability caused by relapses in multiple sclerosis: A different approach

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. COVID-19 in people with multiple sclerosis: A global data sharing initiative

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: In multiple sclerosis (MS) the quantitative role of relapses in Expanded Disability Status Scale (EDSS) worsening beyond the recovery phase is not well known. Most studies have examined the predictive role of early relapses in more distant endpoints. Relapses and worsening may be associated because they could be independent effects of the same underlying disease characteristics without causal relationship. With the design of the present study we aim to estimate the direct effect on disability of relapses.

METHODS: We used data from the obligatory bi-annually registration in the Danish Multiple Sclerosis Registry of relapses and EDSS for all patients treated with disease modifying drugs for relapsing/remitting MS from 1996 to 2015 with exclusion of patients in whom no relapses had ever been recorded during treatment. We paired two consecutive control periods into study intervals which were the actual study units. Study intervals were qualified and included if they were at length 12-24 months, with EDSS ≤ 5.5 at start, and if a preceding relapse had been no closer than nine months to the EDSS assessment at the start or end of the study interval to eliminate relapse-related temporary EDSS worsening. We compared EDSS worsening in study intervals with and without relapses. The same patients could contribute with study intervals with and without relapses. For statistical analyses we used Generalized Estimating Equations to account for intra-patient correlations.

RESULTS: We analysed 5187 study intervals from 2015 MS patients. The mean of EDSS increase was 0.205 units in qualifying study intervals with relapses and 0.065 without relapses when adjusted for length of study interval, sex, and EDSS at start of interval; p < 0.0001. However, the effect of relapses on EDSS was absent in male patients (p = 0.521), and when EDSS was ≥ 4.0 at start of the study interval (p = 0.726).

CONCLUSION: Relapses play an independent and significant role for worsening of MS in patients under disease-modifying therapy (DMT) and eliminating relapses would not only free the patients from the temporary perils of relapses but would also reduce the worsening of the disease.

OriginalsprogEngelsk
TidsskriftMultiple Sclerosis and Related Disorders
Vol/bind32
Sider (fra-til)1-8
Antal sider8
ISSN2211-0348
DOI
StatusUdgivet - jul. 2019

Bibliografisk note

Copyright © 2019. Published by Elsevier B.V.

ID: 58904446